Using this strategy, we previously identified two mRNA based biomarkers, ULBP2 and SEMA5A, for the prognostication of colon cancer [42]; and identified an independent gene panel for prediction of prognosis in both diffuse and intestinal type gastric cancer (unpublished data); which shows that the growing transcriptomic data enables discovery of such biomarkers which could have been missed when less patients studied. This evidence concerns the gene SEMA5A and malignant colon neoplasm.